Atezolizumab Plus FOLFOX Halves Recurrence in dMMR Stage III Colon Cancer
The ATOMIC trial establishes adjuvant anti-PD-L1 immunotherapy added to standard oxaliplatin-based chemotherapy as a new option for resected deficient mismatch repair stage III colon cancer, a change already reflected in guidelines.
📅 Journal publication: Mar 26, 2026·Last updated: Aug 18, 2026
Atezolizumab enhances survival in dMMR colon cancer.
Exploring new therapies to improve outcomes in stage III mismatch repair-deficient (dMMR) colon cancer is crucial for advancing patient care. The combination of atezolizumab and mFOLFOX6 resulted in a 3-year disease-free survival rate of 86.3% compared to 76.2% with mFOLFOX6 alone, showing a significant benefit. This study suggests adding atezolizumab to standard chemotherapy could be beneficial for stage III dMMR colon cancer patients, though it is associated with higher rates of severe adverse events. Atezolizumab with mFOLFOX6 improves disease-free survival in dMMR colon cancer.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Sinicrope FA, Ou FS, Arnold D, Peters WR, Behrens RJ, Lieu CH, Matin K, Cohen DJ, Potter SL, Nixon AB, Kottschade LA, Kathol E, Frankel WL, Shergill A, Hsu D, Reinacher-Schick A, Mehan P, Gold PJ, Khalil MF, Zemla T, Gatten C, O'Reilly EM, Meyerhardt JA
Citation:Sinicrope FA, Ou FS, Arnold D, et al. Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer. The New England journal of medicine. 2026;394(12):1155-1166. doi:10.1056/NEJMoa2507874